Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation.
Aged
Anilides
/ therapeutic use
Antiviral Agents
/ therapeutic use
Carbamates
/ therapeutic use
Cyclopropanes
Drug Interactions
Drug Monitoring
Female
Genotype
Hepacivirus
/ genetics
Hepatitis C, Chronic
/ drug therapy
Humans
Immunosuppressive Agents
/ therapeutic use
Kidney Failure, Chronic
/ surgery
Lactams, Macrocyclic
Liver Transplantation
Macrocyclic Compounds
/ therapeutic use
Male
Middle Aged
Proline
/ analogs & derivatives
Ritonavir
/ therapeutic use
Sulfonamides
Valine
Virus Activation
Direct-acting antiviral
Hepatitis C virus
Liver transplantation
Ombitasvir/paritaprevir/ritonavir
Reinfection
Journal
Clinical journal of gastroenterology
ISSN: 1865-7265
Titre abrégé: Clin J Gastroenterol
Pays: Japan
ID NLM: 101477246
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
16
04
2018
accepted:
04
07
2018
pubmed:
12
7
2018
medline:
5
3
2019
entrez:
12
7
2018
Statut:
ppublish
Résumé
We report three cases of genotype 1b hepatitis C virus (HCV) reinfection after liver transplantation. When antiviral treatment was considered, all three patients had renal dysfunction and had been treated with immunosuppressive agents for a long time; one with tacrolimus (TAC) and the others with cyclosporine A (CyA). Therefore, the possible antiviral regimens among direct-acting antivirals (DAA) were limited and so we treated all three patients with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r). Because ritonavir is known to markedly increase the blood concentration of TAC and CyA through drug-drug interactions, close monitoring of blood concentrations of TAC or CyA and dose adjustments of immunosuppressive agents were needed. Sustained virus response was achieved in all the patients treated, and there were no adverse effects or transplant rejection. OBV/PTV/r might be a useful DAA regimen for patients with genotype 1 HCV reinfection in the setting of renal dysfunction.
Identifiants
pubmed: 29995231
doi: 10.1007/s12328-018-0884-y
pii: 10.1007/s12328-018-0884-y
doi:
Substances chimiques
Anilides
0
Antiviral Agents
0
Carbamates
0
Cyclopropanes
0
Immunosuppressive Agents
0
Lactams, Macrocyclic
0
Macrocyclic Compounds
0
Sulfonamides
0
ombitasvir
2302768XJ8
Proline
9DLQ4CIU6V
Valine
HG18B9YRS7
Ritonavir
O3J8G9O825
paritaprevir
OU2YM37K86
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
63-70Subventions
Organisme : Japan Society for the Promotion of Science
ID : 15K08492
Références
Am J Transplant. 2015 May;15(5):1313-22
pubmed: 25708713
Lancet. 1997 Mar 22;349(9055):825-32
pubmed: 9121257
Hepatol Res. 2016 Jun;46(7):707-12
pubmed: 26439054
Hepatol Res. 2014 Jan;44 Suppl S1:59-70
pubmed: 24397840
Liver Transpl. 2004 Oct;10(10):1240-7
pubmed: 15376304
Transplantation. 2014 Nov 15;98(9):994-9
pubmed: 25099704
Hepatology. 2014 Jun;59(6):2083-91
pubmed: 24604476
N Engl J Med. 2014 Dec 18;371(25):2375-82
pubmed: 25386767
J Hepatol. 2017 Jan;66(1):153-194
pubmed: 27667367
Hepatology. 2015 Oct;62(4):1037-46
pubmed: 26147154
Liver Transpl. 2013 Jan;19(1):3-26
pubmed: 23281277
Transpl Int. 2014 Aug;27(8):767-74
pubmed: 24684710
World J Gastroenterol. 2015 Oct 14;21(38):10760-75
pubmed: 26478668
J Hepatobiliary Pancreat Sci. 2015 Feb;22(2):144-50
pubmed: 25338946
J Hepatol. 2008 Aug;49(2):274-87
pubmed: 18571272
Hepatology. 2015 Sep;62(3):932-54
pubmed: 26111063
Hepatol Res. 2017 Dec;47(13):1429-1437
pubmed: 28457003
J Gastroenterol. 2018 Jan;53(1):119-128
pubmed: 28560477
Gastroenterology. 2012 May;142(5):1132-1139.e1
pubmed: 22285805
N Engl J Med. 2014 May 15;370(20):1889-98
pubmed: 24725239
Gastroenterology. 2015 Jan;148(1):108-17
pubmed: 25304641
J Formos Med Assoc. 2018 Jun;117(6):518-526
pubmed: 28662883
Clin J Gastroenterol. 2017 Apr;10(2):179-184
pubmed: 28224470